September 21, 2020

SPRINGWORKS THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH JANSSEN TO EVALUATE NIROGACESTAT IN COMBINATION WITH TECLISTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

SpringWorks Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical collaboration and supply agreement with Janssen Biotech, Inc. (Janssen) to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, teclistamab, in patients with relapsed or refractory multiple myeloma. Read more here